Search Results
Co-Lead Manager on Savara Inc.'s Underwritten Offering
Oppenheimer & Co. Inc. acted as Co-Lead Manager on Savara Inc.’s $79,994,334 Underwritten Offering of Common Stock and Pre-Funded Warrants
Bookrunner on Viking Therapeutics, Inc.'s Follow-On Offering
Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 5,750,000 shares of its common stock at a price to the public of $30.00 per share.
Biopharma Private Placement Insights (Q3'23)
The latest editions of Oppenheimer’s Quarterly Private Placement Insights Report and FDA & IRA Insights Report are now available upon request.
Biopharma Private Placement Insights (Q2'23 and FY'22)
The latest edition of Oppenheimer & Co. Inc.’s Quarterly Biopharma M&A and Strategic Collaboration Insights Report is now available upon request.
Biopharma Private Placement Insights (Q1'23 and FY'22)
The latest edition of Oppenheimer & Co. Inc.’s Quarterly Biopharma M&A and Strategic Collaboration Insights Report is now available upon request.
Biopharma M&A and Strategic Collaboration Insights (Q3'23)
The latest edition of Oppenheimer & Co. Inc.’s Quarterly Biopharma M&A and Strategic Collaboration Insights Report is now available upon request.
Biopharma M&A and Strategic Collaboration Insights (Q2'23)
The latest edition of Oppenheimer & Co. Inc.’s Quarterly Biopharma M&A and Strategic Collaboration Insights Report is now available upon request.
Biopharma M&A and Strategic Collaboration Insights (Q1'23 and FY'22)
The latest edition of Oppenheimer & Co. Inc.’s Quarterly Biopharma M&A and Strategic Collaboration Insights Report is now available upon request.
You Can't Keep a Good Bond Yield Down
Should issuers stay on the sidelines amid the varied rate headwinds, such lower supply scenario could turn out to be a small gift for October Muni returns, with munis possibly outperforming a further sell-off.
With a Debt Ceiling Deal in Hand, Focus is on the Fed
What had previously been overbought and rich areas of the muni market, are now offering better entry points to lock in higher cash flows and potentially stronger portfolio returns should yields demonstrate meaningful contraction